Cassava Sciences Inc (SAVA)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

7801 N CAPITAL OF TEXAS HIGHWAY AUSTIN, TX 78731

Operates as a development-stage biopharmaceutical company that develops novel drugs targeting severe chronic pain such as pain associated with advanced osteoarthritis, low-back pain or irritable bowel syndrome.

Data as of 2020-10-17
Market Cap261.155 Million Shares Outstanding24.919 Million Avg 30-day Volume13.393 Million
P/E Ratio Dividend Yield EPS-0.23
Price/Sales Price cash flow ratio Price free cash flow ratio-103.4
Book Value0.97 Price to Tangible Book11.22 Alpha0.08
Short Interest Ratio % Short Interest to Float R-squared0.016044
BETA1.6323 52-week High/Low12.68 / 1.05 Stddev0.553449

Are you looking for this stock instead?

View SEC Filings from SAVA instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding SAVA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SAVA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

272 Thousand total shares from 5 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BARBIER REMI PRESIDENT AND CEO

  • Officer
  • Director
1,078,855 2020-09-24 6

ROBERTSON SANFORD

  • Director
912,623 2020-09-18 5

SCHOEN ERIC CHIEF FINANCIAL OFFICER

  • Officer
27,300 2020-09-17 2

FRIEDMANN NADAV CHIEF MEDICAL & OPERATING OFF.

  • Officer
  • Director
0 2019-12-13 1

GUSSIN ROBERT Z

  • Director
0 2019-12-13 1

SCANNON PATRICK J MD PHD

  • Director
0 2019-12-13 1

O DONNELL MICHAEL J

  • Director
0 2019-12-13 1

RAMASASTRY SAIRA

  • Director
0 2019-12-13 1

ARMISTICE CAPITAL, LLC

ARMISTICE CAPITAL MASTER FUND LTD.

BOYD STEVEN

  • 10% Owner
No longer subject to file 2018-10-03 0

RODDY PETER S CHIEF FINANCIAL OFFICER

  • Officer
121,479 2016-04-08 0

SCHOENHARD GRANT CHIEF SCIENTIFIC OFFICER

  • Officer
78,551 2014-07-11 0

SABRETOOTH MASTER FUND, L.P.

SABRETOOTH CAPITAL PARTNERS, LLC

SABRETOOTH CAPITAL MANAGEMENT, LLC

KALIR EREZ

PERRY CRAIG

  • 10% Owner
No longer subject to file 2011-10-03 0

EASTBOURNE CAPITAL MANAGEMENT LLC/CA

  • 10% Owner
No longer subject to file 2009-09-25 0

BLACK BEAR OFFSHORE MASTER FUND LP

  • 10% Owner
No longer subject to file 2009-07-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

BARBIER REMI - Director - Officer PRESIDENT AND CEO

2020-09-24 16:49:36 -0400 2020-09-24 P 10,000 $9.59 a 1,078,855 direct -2.7027 -7.0619 0.3487 4 -7.0619 6

ROBERTSON SANFORD - Director

2020-09-21 16:01:33 -0400 2020-09-18 P 36,281 $8.92 a 912,623 direct -6.6029 9.1866 9.7608 4 -7.0813 3

ROBERTSON SANFORD - Director

2020-09-17 17:15:41 -0400 2020-09-17 P 213,719 $6.98 a 876,342 direct -2.4826 13.9027 13.9027 6 -3.575 5

SCHOEN ERIC - Officer CHIEF FINANCIAL OFFICER purchase by schoen family llc. reporting person is a member of the schoen family llc.

2020-09-17 17:25:33 -0400 2020-09-17 P 2,000 $7.04 a 27,300 indirect -2.4826 13.9027 13.9027 6 -3.575 5

SCHOEN ERIC - Officer CHIEF FINANCIAL OFFICER

2020-09-17 17:25:33 -0400 2020-09-17 P 10,000 $7.03 a 25,300 direct -2.4826 13.9027 13.9027 6 -3.575 5

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments